Oncotelic Therapeutics Advances AI-Powered GMP Manufacturing Platform with TechForce Robotics

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, marking a significant step toward commercializing an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.

According to the company, the integrated platform combines PDAOAI with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing. This integration creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO). Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.

The advancement is particularly noteworthy as the pharmaceutical industry increasingly seeks automation and AI solutions to improve efficiency, reduce errors, and accelerate production timelines. Oncotelic's proprietary PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration, is now being applied to manufacturing operations, potentially setting a new standard for GMP compliance and operational excellence.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio.

The successful Phase 2 completion positions Oncotelic to potentially offer its AI-powered manufacturing platform to other pharmaceutical companies, creating a new revenue stream through software licensing and automation services. The company's participation at the BIO International Convention 2026 will likely attract significant interest from potential partners and customers looking to modernize their manufacturing operations. As the platform moves toward commercialization, it could play a pivotal role in reshaping how pharmaceutical products are manufactured, with implications for product quality, cost reduction, and speed to market.

For more information, visit the company's newsroom at https://nnw.fm/OTLC. The full press release is available at https://nnw.fm/j1n43.